Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4017

Sort by

Sort Order Select

Journal Articles

The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort

Blood blood.2025029916.

https://doi.org/10.1182/blood.2025029916

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

Blood (2025) 146 (12): 1440–1449.

https://doi.org/10.1182/blood.2024027902

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jérôme Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean-Benoît Arlet, Jérémie Dion, Maël Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thépot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoît Faucher, Estibaliz Lazaro, Véronique Morel, Antoine Néel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cédric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean-Baptiste Rieu, Olivier Fain, Sophie Georgin-Lavialle, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène Mékinian, Thibault Comont

Blood (2025) 146 (12): 1450–1461.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood blood.2025028823.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)

Terri Parker, Adam Landon Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius K. Girnius, Patrick Hagen, Emma C Scott, Antje Hoering, Brian G.M. Durie, Robert Z Orlowski

Blood blood.2024027962.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Blood blood.2025029909.

https://doi.org/10.1182/blood.2025029909

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Blood blood.2025028550.

https://doi.org/10.1182/blood.2025028550

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Ilaria Romano, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Eleonora Calabretta, Stephane Chauvie, Francesco Corrado, Stefania Crisci, Marco Cuzzocrea, Rosaria De Filippi, Bernhard Gerber, Michał Kurlapski, Luigi Maria Larocca, Elisabetta Merlo, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Alexandar Tzankov, Carmelo Carlo-Stella, Gianluca Gaidano, Luca Ceriani, Emanuele Zucca, Davide Rossi

Blood (2025) 146 (10): 1207–1224.

https://doi.org/10.1182/blood.2024027355

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical and molecular features of immunodeficiency in patients with telomere biology disorders

Luiz Fernando Bazzo Catto, Nidhi Aggarwal, Ruba Shalhoub, Xiaoyang Ma, Ivana Darden, Tania Machado, Yue Zhang, Neelam R. Redekar, Natthakan Thongon, Simona Colla, Geraldine Aubert, Cynthia E. Dunbar, Colin O. Wu, Neal S. Young, Bhavisha A. Patel, Fernanda Gutierrez-Rodrigues, Emma M. Groarke

Blood (2025) 146 (10): 1187–1193.

https://doi.org/10.1182/blood.2024026735

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (9): 1051–1064.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia

Blood blood.2025029532.

https://doi.org/10.1182/blood.2025029532

Published: 2025

Includes: Supplemental data

Journal Articles

LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL

Manon Delafoy, Mickaël Frédéric Bonnet, Etienne Lengliné, Agata Cieslak, Aurore Touzart, Estelle Balducci, Mathieu Simonin, Véronique Lheritier, Marie-Emilie Dourthe, Benoit Heid-Picard, Sylvain Latour, Hervé Dombret, Philippe Rousselot, André Baruchel, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi

Blood blood.2025030161.

https://doi.org/10.1182/blood.2025030161

Published: 2025

Includes: Supplemental data

Journal Articles

Artificial Intelligence in Hematology

Aziz Nazha, Olivier Elemento, Sanjay Ahuja, Barbara D Lam, Moses Miles, Roni Shouval, Shannon K. McWeeney, Shireen Sirhan, Andrew Srisuwananukorn, Torsten Haferlach

Blood blood.2025029876.

https://doi.org/10.1182/blood.2025029876

Published: 2025

Includes: Supplemental data

Journal Articles

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia

Matthew S. Davids, Saad S. Kenderian, Ian Flinn, Brian T. Hill, Michael Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Enrique Granados, Javier Pinilla-Ibarz

Blood (2025) 146 (8): 938–943.

https://doi.org/10.1182/blood.2024027460

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT

Eduard Schulz, Lauren M. Curtis, Noa G. Holtzman, Seth M. Steinberg, Kaska Wloka, Alen Ostojic, Alain Mina, Najla El Jurdi, Filip Pirsl, Ashley Carpenter, Mahshid Golagha, Arlene Sirajuddin, Theo Heller, Brian C. Shaffer, Frances T. Hakim, Jeffrey S. Rubin, Ronald E. Gress, Steven Z. Pavletic

Blood (2025) 146 (8): 944–950.

https://doi.org/10.1182/blood.2024028303

Published: 2025

Includes: Supplemental data

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Clinical and molecular features of immunodeficiency in patients with telomere biology disorders

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia

LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALL

Artificial Intelligence in Hematology

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only